
Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 30, 2024
Language: Английский
Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 30, 2024
Language: Английский
Phytomedicine, Journal Year: 2024, Volume and Issue: unknown, P. 156032 - 156032
Published: Sept. 1, 2024
Language: Английский
Citations
2International Journal of Medical Sciences, Journal Year: 2024, Volume and Issue: 21(13), P. 2464 - 2479
Published: Jan. 1, 2024
MAPKK4 has been implicated in the pathological mechanisms underlying myocardial and vascular injury, specifically influencing endothelial cell damage programmed death via subcellular pathways. Nevertheless, regulatory role of coronary microvascular injury following infarction remains unconfirmed, exploration targeted mitochondrial protective therapeutic agents unaddressed. In light this gap, we established a gene-modified mouse model ischemia-reperfusion employed Buyang Huanwu decoction (BYHW), traditional cardiovascular formula, to assess its efficacy treating post-ischemia-reperfusion. The study aimed elucidate mechanism by which BYHW mitigates induced through attenuation apoptosis. Experimental outcomes revealed that high-dose significantly ameliorated post-ischemia-reperfusion, restoring structural integrity microvasculature reducing inflammation oxidative stress. Contrarily, transgenic mice overexpressing MAPKK4, intervention failed attenuate To further investigate, simulated hypoxia/reoxygenation cells using MAPKK4-related cellular gene modification model. results indicated attenuates inflammatory enhances viability hypoxic stress, inhibiting apoptosis pathway. However, overexpression MAPKK4/p38 negated effects BYHW, showing no impact on stress under conditions. Molecular interaction studies confirmed active components Astragaloside IV Ligustrazine, interact with MAPKK4/P38 axis.
Language: Английский
Citations
1Computer Methods in Biomechanics & Biomedical Engineering, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 25
Published: Nov. 13, 2024
Liujunzi decoction (LJZD) is commonly used to treat hepatitis B virus (HBV), though its active ingredients and mechanisms are not fully known. This study identified core targets components of LJZD for treating (HB) through network pharmacology, molecular docking, dynamics simulation. Screening from databases yielded 533 components, 2619 LJZD, 2910 HB, with 891 intersecting targets. STRING CytoHubba analyses AR VDR as targets, key pathways including PI3K-Akt MAPK. The findings clarify LJZD's multicomponent, multitarget mechanisms, supporting clinical application HB treatment.
Language: Английский
Citations
1Current Pharmaceutical Design, Journal Year: 2024, Volume and Issue: 30(35), P. 2785 - 2796
Published: Aug. 2, 2024
Fufang Banmao capsule (FFBM), a traditional Chinese medicine, has been used to treat primary liver cancer (PLC) for several years. However, the bioactive ingredients, and mechanism of FFBM treating PLC remains unclear. Our objective is utilize network pharmacology investigate these aspects subsequently validate their effectiveness through clinical data.
Language: Английский
Citations
0Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 30, 2024
Language: Английский
Citations
0